Complementary arguments in favor of the betacytotrophic action of the hypglycemic sulfonamides.
D000818:Animals; D003920:Diabetes Mellitus / Q000188:drug therapy*; D003981:Diazoxide / Q000627:therapeutic use; D004285:Dogs; D005947:Glucose / Q000378:metabolism; D006965:Hyperplasia / Q000378:metabolism; D007003:Hypoglycemia; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000096:biosynthesis / Q000378:metabolism; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000187:drug effects* / Q000378:metabolism; D051379:Mice; D010180:Pancreatectomy; D051381:Rats; D014044:Tolbutamide / Q000627:therapeutic use
D007004:Hypoglycemic Agents; D007328:Insulin; D014044:Tolbutamide; D005947:Glucose; D003981:Diazoxide